EUVIMEDEUVIMED entdecken
BeobachtungsstudieStudienprotokollOpen Access

Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study

Basak Tas iD, Will Lawn iD, Marianne Jauncey iD, Mark Bartlett iD, Paul Dietze iD, Daniel O'Keefe iD, Nico Clark iD, Bruce Henderson iD, Catriona Cowan iD, Osian Meredith iD, John Strang iD

JMIR Research Protocols · 2024

DOI: 10.2196/57367 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JMIR Research Protocols, 2024. Verfasst von Basak Tas und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Wearable Electronic Devices. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Opioid overdose is a global health crisis, affecting over 27 million individuals worldwide, with more than 100,000 drug overdose deaths in the United States in 2022-2023. This protocol outlines the development of the PneumoWave chest biosensor, a wearable device being designed to detect respiratory depression in real time through chest motion measurement, intending to enhance early intervention and thereby reduce fatalities.

Objective

The study aims to (1) differentiate opioid-induced respiratory depression (OIRD) from nonfatal opioid use patterns to develop and refine an overdose detection algorithm and (2) examine participants’ acceptability of the chest biosensor.

Methods

The study adopts an observational design over a 6-month period. The biosensor, a small device, will be worn by consenting participants during injecting events to capture chest motion data. Safe injecting facilities (SIF) in Melbourne, Victoria (site 1), and Sydney, New South Wales (site 2), which are legally sanctioned spaces where individuals can use preobtained illicit drugs under medical supervision. Each site is anticipated to recruit up to 100 participants who inject opioids and attend the SIF. Participants will wear the biosensor during supervised injecting events at both sites. The biosensor will attempt to capture data on an anticipated 40 adverse drug events. The biosensor’s ability to detect OIRD will be compared to the staff-identified events that use standard protocols for managing overdoses. Measurements will include (1) chest wall movement measured by the biosensor, securely streamed to a cloud, and analyzed to refine an overdose detection algorithm and (2) acute events or potential overdose identified by site staff. Acceptability will be measured by a feedback questionnaire as many times as the participant is willing to throughout the study.

Results

As of April 2024, a total of 47 participants have been enrolled and data from 1145 injecting events have already been collected, including 10 overdose events. This consists of 17 females and 30 males with an average age of 45 years. Data analysis is ongoing.

Conclusions

This protocol establishes a foundation for advancing wearable technology in opioid overdose prevention within SIFs. The study will provide chest wall movement data and associated overdose data that will be used to train an algorithm that allows the biosensor to detect an overdose. The study will contribute crucial insights into OIRD, emphasizing the biosensor’s potential step forward in real-time intervention strategies. International Registered Report Identifier (IRRID) DERR1-10.2196/57367

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wearable Electronic DevicesHumansMaleFemaleDrug OverdoseOpiate OverdoseAdultMiddle AgedAnalgesics, OpioidBiosensing TechniquesObservational Studies as TopicNew South WalesRespiratory Insufficiency

Stichwörter der Autor:innen

AustraliaUnited Statesalgorithmbiosensorchest biosensordetection algorithmdrug overdoseillicit drugsinjecting opioid usemedically supervised injection centermobile phonenaloxoneobservational designopioid induced respiratory depressionopioid overdose

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.
  • Medically Supervised Injecting Centre, Sydney, Australia.
  • Disease Elimination, Burnet Institute, Melbourne, Australia.
  • Royal Melbourne Hospital, Melbourne, Australia.
  • PneumoWave LTD, Motherwell, United Kingdom.

ORCID-Profile: Basak Tas, Will Lawn, Marianne Jauncey, Mark Bartlett, Paul Dietze, Daniel O'Keefe, Nico Clark, Bruce Henderson, Catriona Cowan, Osian Meredith, John Strang

Zitieren

APA

Tas, B., Lawn, W., Jauncey, M., Bartlett, M., Dietze, P., O'Keefe, D., Clark, N., Henderson, B., Cowan, C., Meredith, O., & Strang, J. (2024). Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study. JMIR Research Protocols. https://doi.org/10.2196/57367

Vancouver

Tas B, Lawn W, Jauncey M, Bartlett M, Dietze P, O'Keefe D, et al. Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study. JMIR Research Protocols. 2024. doi:10.2196/57367

BibTeX
@article{Tas2024,
  author = {Tas, Basak and Lawn, Will and Jauncey, Marianne and Bartlett, Mark and Dietze, Paul and O'Keefe, Daniel and Clark, Nico and Henderson, Bruce and Cowan, Catriona and Meredith, Osian and Strang, John},
  title = {Overdose Detection Among High-Risk Opioid Users Via a Wearable Chest Sensor in a Supervised Injecting Facility: Protocol for an Observational Study},
  journal = {JMIR Research Protocols},
  year = {2024},
  doi = {10.2196/57367}
}
Kostenlos starten →